We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Oligometastatic cancer
Digital Poster
Clinical
Integrating Stereotactic Ablative Body Radiotherapy (SABR) on systemic therapy for oligometastatic cancer: Real-World Multicentre Experience
David Woolf, United Kingdom
-457
Progression-Directed Ablative Radiotherapy Improves Event-Free Survival in Oligoprogressive NSCLC
Lorenzo De Sanctis, Italy
-1289
Stereotactic Body Radiotherapy (SBRT) for Rib Metastases: Local Control and Toxicity Outcomes From a Contemporary Institutional Cohort
Darren MC Poon, China, Hong Kong Special Administrative Region
-1983
Prognostic Significance of New Versus Pre-Existing Lesions in Oligoprogressive Disease Treated with SABR.
Curtis Leclerc, Canada
-2370
Modeling overall survival in patients with oligometastatic non–small cell lung cancer based on longitudinal cancer dynamics
Maksym Fritsak, Switzerland
-2917
Stereotactic radiotherapy for non-spine bone metastases: a mono-institutional experience
Francesco Cuccia, Italy
-3181
Safety and Effectiveness of All-in-one Emergency Radiotherapy in Metastatic Vertebral Malignancies
sun haitao, China
-3344
Liver stereotactic body radiotherapy in oligometastatic disease: 10 years of institutional experience
João Silva, Portugal
-3499
SBRT for Lung Oligometastatic Hepatocellular Carcinoma : Outcomes and Prognostic Factors
SOO JIN LEE, Korea Republic of
-3612
Stereotactic MR-Guided Adaptive Radiotherapy (SMART) for Liver Metastases: Single Institution Experience
Enis Ozyar, Turkey
-3650
1.5T MR-guided adaptive stereotactic radiotherapy for liver metastases with intrafraction tracking and gating using Comprehensive Motion Management
Chiara De-Colle, Italy
-3712
Local control after SBRT for liver lesions: helical vs robotic IMRT.
Andrei Fodor, Italy
-4029
Long-term RECIST and volumetric responses after 5-fraction stereotactic ablative radiotherapy for adrenal metastases
Nicolas Giraud, France
-4172
Outcomes after repeated stereotactic body radiotherapy for oligometastatic colorectal cancer
Dania Al-Toma, The Netherlands
-4224
Definitive Stereotactic Body Radiotherapy Versus Minimal Access Separation Surgery plus SBRT for Spinal Metastases: A Propensity-Matched Analysis
Michael Yan, Canada
-4273
MR-guided adaptive stereotactic radiotherapy for oligometastatic prostate cancer: clinical and radiographic outcomes
Andrew Mcpartlin, Canada
-4332
Feasibility and safety of MR-guided adaptive SABR for re-irradiation of adrenal metastases
Miguel A. Palacios, The Netherlands
-4542
Stereotactic Body Radiotherapy for Oligometastatic Disease in Elderly Patients: Outcomes and Predictive Factors of Efficacy
Antonio Marco Marzo, Italy
-4627
Long term Outcomes following stereotactic ablative radiotherapy (SABR) for Melanoma Liver Metastases
Meenakshi Jeeva, Canada
-4792
Survival Outcomes After Consolidative Radiotherapy for Hormone-Sensitive Prostate Cancer with Synchronous Non-Regional Node (M1a) Metastases
Kayeong Shin, USA
-4877
Comparable survival in synchronous N1M0 and M1a hormone-sensitive prostate cancer after whole-pelvic radiotherapy and elective nodal irradiation
Kayeong Shin, USA
-5067